XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Stock Incentive Plans
6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Stock Incentive Plans
17.
STOCK INCENTIVE PLANS

In connection with the closing of the Business Combination, the 2021 Equity Incentive Plan (the "2021 Plan") was adopted and approved by the Company's board of directors.

Prior to the Business Combination, the Company maintained its 2017 Stock Option Plan (the “2017 Plan”).

Upon the adoption and approval of the 2021 Plan, the 2017 Plan was terminated and each outstanding vested or unvested option, as required under the 2017 Plan, was converted to the 2021 Plan, multiplied by the Exchange Ratio, with the same key terms and vesting requirements.

Awards granted under the 2017 Plan had time-based vesting or performance-based with a market condition vesting requirements. Stock options granted under the 2017 Plan expire on the tenth anniversary of the grant date.

Additionally, the Company maintained a Phantom Stock Plan (the “Phantom Plan”), which provided for the issuance of phantom shares of CCCIS’s common stock (“Phantom Shares”) to eligible employees under the 2017 Plan. Awards under the Phantom Plan were settled in cash and thus accounted for as liability awards.

Phantom Shares vested under the same time-based or performance-based with a market condition as the stock options granted under the 2017 Plan. Upon consummation of the Business Combination, the outstanding Phantom Shares were settled in cash in November 2021.

Stock OptionsThe table below summarizes the option activity for the six months ended June 30, 2022:

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

 

 

Weighted-

 

 

Remaining

 

 

Aggregate

 

 

 

 

 

 

Average

 

 

Contractual

 

 

Intrinsic

 

 

 

 

 

 

Exercise

 

 

Life

 

 

Value

 

 

 

Shares

 

 

Price

 

 

(in years)

 

 

(in thousands)

 

Options outstanding—December 31, 2021

 

 

55,644,495

 

 

$

2.95

 

 

 

6.0

 

 

$

469,591

 

Exercised

 

 

(5,682,071

)

 

 

2.71

 

 

 

 

 

 

 

Forfeited and canceled

 

 

(222,234

)

 

 

4.67

 

 

 

 

 

 

 

Options outstanding—June 30, 2022

 

 

49,740,190

 

 

$

2.97

 

 

 

5.4

 

 

$

309,841

 

Options exercisable—June 30, 2022

 

 

45,634,668

 

 

$

2.73

 

 

 

5.1

 

 

$

295,200

 

Options vested and expected to vest—June 30, 2022

 

 

49,436,255

 

 

$

2.95

 

 

 

5.3

 

 

$

308,786

 

The fair value of the options vested during the six months ended June 30, 2022 was $8.1 million.

Restricted Stock Units—Restricted Stock Units (“RSUs”) are convertible into shares of the Company’s common stock upon vesting.

During the six months ended June 30, 2022, the Company granted 15,561,624 RSUs, of which 14,191,160 have time-based vesting requirements, 685,257 have performance-based vesting requirements and 685,207 have performance-based with a market condition vesting requirements.

The valuation of the performance-based RSUs with a market condition granted during the six months ended June 30, 2022 was determined using a Monte Carlo simulation model using the following assumptions:

Expected term (in years)

 

2.8

 

Expected volatility

 

35%

 

Expected dividend yield

 

0%

 

Risk-free interest rate

 

2.28%

 

Fair value at valuation date

 

$

7.42

 

The table below summarizes the RSU activity for the six months ended June 30, 2022:

 

 

 

 

 

Weighted-

 

 

 

 

 

 

Average

 

 

 

Shares

 

 

Fair Value

 

Non-vested RSUs—December 31, 2021

 

 

18,558,211

 

 

$

10.74

 

Granted

 

 

15,561,624

 

 

 

10.14

 

Vested

 

 

(103,124

)

 

 

9.68

 

Forfeited

 

 

(701,723

)

 

 

11.08

 

Non-vested RSUs—June 30, 2022

 

 

33,314,988

 

 

 

10.46

 

Employee Stock Purchase Plan—As of June 30, 2022, 6,031,714 shares of common stock are reserved for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP increases on January 1 by the lesser of 1% of the total numbers of shares outstanding or a lesser amount as determined by the board of directors.

As of June 30, 2022, no shares had been sold under the ESPP.

Stock-Based Compensation—Stock-based compensation expense has been recorded in the accompanying condensed consolidated statements of operations and comprehensive income (loss) as follows for the three and six months ended June 30, 2022 and 2021 (in thousands):

 

 

 

For the Three Months Ended

 

 

For the Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Cost of revenues

 

$

1,661

 

 

$

176

 

 

$

2,510

 

 

$

394

 

Research and development

 

 

5,530

 

 

 

700

 

 

 

9,060

 

 

 

1,275

 

Sales and marketing

 

 

6,611

 

 

 

735

 

 

 

11,441

 

 

 

1,289

 

General and administrative

 

 

14,601

 

 

 

1,272

 

 

 

29,036

 

 

 

12,579

 

Total stock-based compensation expense

 

$

28,403

 

 

$

2,883

 

 

$

52,047

 

 

$

15,537

 

 

 

As of June 30, 2022, there was $203.7 million of unrecognized stock compensation expense related to non-vested time-based awards which is expected to be recognized over a weighted-average period of 3.3 years. As of June 30, 2022, there was $93.5 million of unrecognized stock-based compensation expense related to non-vested performance-based awards.